Informations sur le produit
- 3-Hydroxy-2-(4-methoxy-phenyl)-5-(2-methylamino-ethyl)-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-oneDeacetyl N-monodesmethyl diltiaze m
- 1,5-benzothiazepin-4(5H)-one, 2,3-dihydro-3-hydroxy-2-(4-methoxyphenyl)-5-[2-(methylamino)ethyl]-
O-Desacetyl-N-desmethyl diltiazem (ODDMD) is a prodrug of diltiazem that is hydrolyzed to its active form in the body. ODDMD has been shown to have beta-blocker properties and to inhibit angiotensin II. It also has been shown to have calcium channel blocker effects, which may be useful for treating high blood pressure and preventing cardiovascular diseases. The pharmacokinetics of ODDMD are not well understood, but it is known that plasma concentrations of this drug can be increased with food intake.